Norvik Enterprises Limited

Norvik Enterprises Limited is a pharmaceutical importer and distributor based in Kampala, Uganda. Established in 1998, the company was founded with the primary objective of meeting the increasing demand for affordable and high-quality pharmaceutical products. Over the years, Norvik has grown to become one of Uganda's leading importers of pharmaceutical, vaccine, and medical sundry products. The company imports products from reputable manufacturers worldwide, including the UK, USA, Europe, Asia, South Africa, and Australia. (norvik.ug)

Norvik Enterprises Limited operates a comprehensive distribution network across Uganda, supplying to various regions such as Soroti City, Mbarara City, Fort Portal City, Kasese City, Gulu City, Kabale City, Masaka City, Mbale City, Jinja City, and Hoima City. This extensive reach ensures that essential pharmaceutical products are accessible to both urban and remote areas. The company's services encompass procurement, warehousing, distribution, sales, and marketing, enabling a continuous flow of life-saving drugs and health products to facilities nationwide. (norvik.ug)

Norvik Enterprises Limited maintains warehousing facilities in the heart of Kampala, Uganda, which house over 100 brands of pharmaceutical products and surgical tools from various pharmaceutical companies. These products are well-distributed through the company's branches across the country, including locations in Mbarara and Mbale. The warehousing facilities are equipped with numerous fire extinguishers for safety, as well as machinery like ladder platforms and skilled manpower to ensure smooth and efficient operations. (norvik.ug)

In Kenya's pharmaceutical supply chain, Norvik Enterprises Limited functions as a pharmaceutical importer and distributor. While the company is based in Uganda, it has been involved in importing pharmaceutical products from India, as evidenced by its trade data. This involvement indicates that Norvik Enterprises Limited plays a role in the regional distribution of pharmaceutical products, potentially supplying to neighboring countries, including Kenya. (en.nbd.ltd)

Norvik Enterprises Limited's sourcing strategy exhibits a high concentration, with a significant portion of its imports originating from a single supplier, Aristo Pharmaceuticals Private Limited. This supplier accounts for $1.8 million in imports, representing 96.5% of the company's total shipments. Such dependency on a single supplier can pose risks, including potential supply chain disruptions if issues arise with that supplier. However, this concentration may also reflect a strategic choice to maintain consistent product quality and pricing. The stability of this relationship is crucial for Norvik's operations, and any changes in the supplier's circumstances could significantly impact the company's supply chain.

Norvik Enterprises Limited's supply chain resilience is closely tied to its reliance on Aristo Pharmaceuticals Private Limited. The company's limited engagement with other suppliers—such as Indus Life Sciences Private Limited, Indchemie Health Specialities Private Limited, and others—suggests a lack of diversified sourcing. This limited diversification may expose Norvik to risks associated with supply chain disruptions, such as production delays or quality issues from the primary supplier. Additionally, the company's focus on a narrow range of formulations, primarily in the cardiovascular and diuretics categories, indicates a specialized product portfolio. While this specialization can lead to expertise and efficiency, it also means that any disruptions in the supply of these specific products could have a more pronounced impact on Norvik's operations.

The high concentration of sourcing from a single supplier, Aristo Pharmaceuticals Private Limited, positions Norvik Enterprises Limited to benefit from consistent product quality and potentially favorable pricing. However, this strategy also exposes the company to significant risks, including supply chain disruptions and reduced bargaining power with other suppliers. For Indian exporters seeking to become alternative suppliers to Norvik, there is an opportunity to diversify the company's supply base by offering competitive pricing, reliable delivery schedules, and high-quality products. Building a strong relationship with Norvik could lead to increased market share in the East African region, especially if the company is looking to mitigate risks associated with over-reliance on a single supplier.

In Kenya, the Pharmacy and Poisons Board (PPB) serves as the primary regulatory authority overseeing the importation, distribution, and sale of pharmaceutical products. The PPB ensures that all drugs and health products meet the required safety, efficacy, and quality standards before they enter the Kenyan market. The regulatory framework governing pharmaceutical imports includes the Pharmacy and Poisons Act (Cap. 244) and the Pharmacy and Poisons (Registration of Health Products and Technologies) Rules, which outline the procedures for drug registration, importation, and market authorization.

Importers of pharmaceutical products into Kenya are required to obtain a product registration certificate from the Pharmacy and Poisons Board (PPB) for each drug they intend to import. This process involves submitting an application that includes detailed information about the product, its manufacturing process, and evidence of compliance with Good Manufacturing Practice (GMP) standards. The PPB recognizes GMP certificates from competent regulatory authorities, such as the World Health Organization (WHO) and the European Medicines Agency (EMA). Additionally, importers must obtain an import permit for each consignment, processed through the Kenya National TradeNet System (KESWS). (infotradekenya.go.ke)

Pharmaceutical products imported into Kenya must undergo batch testing to ensure they meet the required quality standards. Stability studies are also conducted to confirm that the products maintain their efficacy and safety throughout their shelf life. Labeling requirements include providing information in English and Kiswahili, detailing the product's name, active ingredients, dosage form, strength, batch number, manufacturing date, expiry date, storage conditions, and the manufacturer's details. Serialization mandates may be implemented to enhance traceability and prevent counterfeit products from entering the market.

In January 2025, the Ministry of Health, through the Pharmacy and Poisons Board (PPB), issued a directive banning the importation, distribution, sale, or handling of unregistered pharmaceutical products in Kenya, particularly those referencing the Indian Pharmacopoeia. This move was aimed at curbing the influx of unregistered drugs into the Kenyan market and ensuring that all pharmaceutical products meet the country's regulatory standards. (citizen.digital)

Norvik Enterprises Limited's product strategy focuses on importing pharmaceutical formulations in the cardiovascular, diuretics, and gastrointestinal therapeutic categories. The company's top five imported products include Telmisartan, Hydrochlorothiazide, Domperidone, Ambroxol, and Ibuprofen Paracetamol, with Telmisartan accounting for the largest import value at $8.8 million. This focus aligns with the prevalent health concerns in the East African region, where cardiovascular diseases and related conditions are significant public health issues. The demand for these products is driven by the need for effective treatments for hypertension, heart failure, and other cardiovascular conditions.

Norvik Enterprises Limited's sourcing strategy is heavily concentrated on importing finished pharmaceutical formulations from India, with a particular emphasis on products manufactured by Aristo Pharmaceuticals Private Limited. This approach suggests a preference for sourcing from suppliers that offer a comprehensive range of products meeting international quality standards. The company's limited engagement with other suppliers indicates a strategic choice to maintain consistency in product quality and supply reliability.

Based on its product mix, Norvik Enterprises Limited primarily serves the wholesale distribution segment of the Kenyan pharmaceutical market. The company's focus on importing and distributing pharmaceutical formulations positions it to supply a wide range of healthcare facilities, including hospitals, clinics, and pharmacies, with essential medications. By ensuring a steady supply of high-quality pharmaceutical products, Norvik plays a crucial role in meeting the healthcare needs of the East African region.

There is a realistic opportunity for new Indian suppliers to engage with Norvik Enterprises Limited, especially those offering products in the cardiovascular, diuretics, and gastrointestinal therapeutic categories. By providing competitive pricing, reliable delivery schedules, and adherence to international quality standards, new suppliers can position themselves as viable alternatives to existing suppliers. Diversifying Norvik's supplier base can enhance supply chain resilience and mitigate risks associated with over-reliance on a single supplier.

Indian exporters seeking to supply pharmaceutical products to Norvik Enterprises Limited and the Kenyan market must ensure that their products are registered with the Pharmacy and Poisons Board (PPB) in Kenya. This involves obtaining a product registration certificate and complying with the PPB's requirements, including providing evidence of Good Manufacturing Practice (GMP) certification from recognized authorities such as the World Health Organization (WHO) or the European Medicines Agency (EMA). Additionally, exporters must adhere to Kenya's import regulations, including obtaining import permits through the Kenya National TradeNet System (KESWS).

To establish a relationship with Norvik Enterprises Limited, Indian exporters should initiate contact by providing detailed product information, including specifications, GMP certifications,